Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05615753 · ClinicalTrials.gov registry record · Phase 1

Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors

A Phase 1 study of Breast Cancer, sponsored by University of Illinois at Chicago.

Completed
Registry status
Phase 1
Development phase
62
Enrollment target
1
Study location

NCT05615753 is a Phase 1 study of Breast Cancer that has completed, run by University of Illinois at Chicago. The registered enrollment target is 62 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05615753, a Phase 1 study of Breast Cancer, has completed, sponsored by University of Illinois at Chicago.

COMPLETED
Registry status
Phase 1
Development phase
62 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test the feasibility of implementing acupuncture intervention in federally qualified health centers oncology clinics for breast cancer survivors.

Conditions Studied

Interventions

  • BEHAVIORAL Acupuncture

Study Locations (1)

Illinois

  • University of Illinois at Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2023-01-12
Est. Completion 2024-10-31
Phase Phase 1

Sponsor

University of Illinois at Chicago

430 total trials

What the Registry Record Tells You About NCT05615753

The ClinicalTrials.gov registry entry for NCT05615753 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Acupuncture is the first listed.

NCT05615753 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05615753 about?

NCT05615753 is a clinical study titled "Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors". The purpose of this study is to test the feasibility of implementing acupuncture intervention in federally qualified health centers oncology clinics for breast cancer survivors.

What is the current status of trial NCT05615753?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2023-01-12. Estimated completion is 2024-10-31.

What conditions does trial NCT05615753 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05615753?

The interventions under investigation include: Acupuncture (BEHAVIORAL).

Who is sponsoring clinical trial NCT05615753?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05615753 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.